ICH Guidelines

ICH Guidelines for Clinical Trials and Global Drug Development: A Complete Overview

May 2, 2025

Formed in 1990, ICH unites regulatory authorities and industry representatives from the U.S., Europe, Japan, and beyond to develop harmonized technical guidelines for pharmaceuticals. Through its Quality, Safety, Efficacy, and Multidisciplinary guidelines, ICH ensures that products meet high standards across global markets while facilitating faster, safer, and more efficient drug development and approval processes.
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

Navigating ICH Q-series Guidelines in Clinical Development

May 7, 2025

digi

ICH Q guidelines cover the quality aspect of pharmaceuticals. These include topics like development, risk management, quality systems, and process validation. While primarily considered during manufacturing phases, their integration into clinical development significantly enhances consistency and regulatory confidence.
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

Timeline of ICH Guideline Evolution and Adoption

May 7, 2025

digi

The ICH was officially founded in 1990 by regulatory authorities and industry associations from Europe (EMA), the United States (FDA), and Japan (PMDA). Its primary goal was to eliminate redundant clinical trials and create a unified system for developing and approving pharmaceuticals globally.
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

Role of ICH in GCP Harmonization Across Regions

May 7, 2025

digi

The ICH was established in 1990 as a tripartite initiative between the EU, US, and Japan. It has since expanded to include regulatory bodies and pharmaceutical industry stakeholders from around the world. The core mission is to achieve greater regulatory harmonization to ensure safe, effective, and high-quality medicines.
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

Data Integrity Considerations Under ICH E6 Guidelines

May 7, 2025

digi

Data integrity refers to the completeness, consistency, and accuracy of clinical trial data throughout its lifecycle. ICH E6 mandates that data must be:
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

Implementing ICH E5 and E17 Guidelines for Multiregional Clinical Trials

May 7, 2025

digi

ICH E5—Ethnic Factors in the Acceptability of Foreign Clinical Data—helps determine whether clinical data generated in one region is acceptable for use in another. This guideline acknowledges that ethnic differences can influence pharmacokinetics, pharmacodynamics, and clinical outcomes.
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

ICH Guidelines for Multiregional Clinical Trials: Understanding E5, E17, and Global Harmonization

May 8, 2025

digi

ICH E5, titled “Ethnic Factors in the Acceptability of Foreign Clinical Data,” was one of the earlier efforts to recognize how demographic and cultural differences might impact the safety, efficacy, or dosage of a drug across populations. The guideline provides a framework to determine if clinical data from one region can be extrapolated to another through a concept called a bridging study.
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

Implementing ICH M4 Guidelines in Global Dossiers

May 8, 2025

digi

ICH M4 defines the framework for organizing information into five key modules. Among these, Modules 2 to 5 are harmonized across ICH regions, while Module 1 is region-specific.
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

Comparative Guide to ICH E2A through E2F for Safety Reporting

May 8, 2025

digi

The E2 guidelines are intended to harmonize safety reporting procedures worldwide. Each module focuses on a different aspect of clinical safety:
Click to read the full article.

ICH Guidelines, Regulatory Guidelines

ICH E9(R1) Addendum: Estimands and Sensitivity Analysis in Clinical Trials

May 8, 2025

digi

An estimand is a precise description of the treatment effect to be estimated in a clinical trial. It connects the study’s objective with the statistical analysis strategy. The estimand clarifies how different post-randomization events—especially intercurrent events—are handled when measuring the treatment effect. This allows for greater transparency and consistency across studies.
Click to read the full article.

ICH Guidelines, Regulatory Guidelines